Amplifying the Red-Emission of Upconverting Nanoparticles for Biocompatible Clinically Used Prodrug-Induced Photodynamic Therapy
Source abstract
Abstract
A class of biocompatible upconverting nanoparticles (UCNPs) with largely amplified red-emissions was developed. The optimal UCNP shows a high absolute upconversion quantum yield of 3.2% in red-emission, which is 15-fold stronger than the known optimal β-phase core/shell UCNPs. When conjugated to aminolevulinic acid, a clinically used photodynamic therapy (PDT) prodrug, significant PDT effect in tumor was demonstrated in a deep-tissue (>1.2 cm) setting in vivo at a biocompatible laser power density. Furthermore, we show that our UCNP-PDT system with NIR irradiation outperforms clinically used red light irradiation in a deep tumor setting in vivo. This study marks a major step forward in photodynamic therapy utilizing UCNPs to effectively access deep-set tumors. It also provides an opportunity for the wide application of upconverting red radiation in photonics and biophotonics.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Luminescence Properties of Advanced Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States
State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, Liaoning 116012, People’s Republic of China
Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu 215123, People’s Republic of China
The Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
Funding
National Institute of Mental Health · University of Massachusetts Medical School, University of Massachusetts · Human Frontier Science Program
References (45)
Show source-provided references
1. Chatterjee D. K. · Adv. Drug Delivery Rev. · 2008 · 60 · 162710.1016/j.addr.2008.08.003 ↗
2. Dolmans D. E. J. G. J. · Nat. Rev. Cancer · 2003 · 3 · 38010.1038/nrc1071 ↗
3. Lovell J. F. · Chem. Rev. · 2010 · 110 · 283910.1021/cr900236h ↗
4. Macdonald I. J. · J. Porphyrins Phthalocyanines · 2001 · 5 · 10510.1002/jpp.328 ↗
5. Borgatti-Jeffreys A. · Am. J. Vet. Res. · 2007 · 68 · 39910.2460/ajvr.68.4.399 ↗
6. Kato H. · Lung Cancer · 2003 · 42 · 10310.1016/S0169-5002(03)00242-3 ↗
7. Collaud S. · Curr. Med. Chem.: Anti-Cancer Agents · 2004 · 4 · 301
8. Dougherty T. J. · J. Natl. Cancer Inst. · 1998 · 90 · 88910.1093/jnci/90.12.889 ↗
9. Huang Z. · Technol. Cancer Res. Treat. · 2005 · 4 · 28310.1177/153303460500400308 ↗
10. Peng Q. · Photochem. Photobiol. · 1997 · 65 · 23510.1111/j.1751-1097.1997.tb08549.x ↗
11. Peng Q. · Cancer · 1997 · 79 · 228210.1002/(SICI)1097-0142(19970615)79:12<2282::AID-CNCR2>3.0.CO;2-O ↗
12. Ericson M. B. · Ther. Clin. Risk Manag. · 2008 · 4 · 110.2147/TCRM.S1769 ↗
13. Ntziachristos V. · Eur. Radiol. · 2003 · 13 · 19510.1007/s00330-002-1524-x ↗
14. Oar M. A. · Chem. Mater. · 2005 · 17 · 226710.1021/cm047825i ↗
15. Wang S. · J. Mater. Chem. · 2004 · 14 · 48710.1039/b311429e ↗
16. Haase M. · Angew. Chem., Int. Ed. · 2011 · 50 · 580810.1002/anie.201005159 ↗
17. Feng W. · Adv. Mater. · 2013 · 25 · 528710.1002/adma.201301946 ↗
18. Wang F. · Analyst · 2010 · 135 · 183910.1039/c0an00144a ↗
19. Wang F. · Chem. Soc. Rev. · 2009 · 38 · 97610.1039/b809132n ↗
20. Wang C. · Biomaterials · 2011 · 32 · 614510.1016/j.biomaterials.2011.05.007 ↗
21. Idris N. M. · Nat. Med. · 2012 · 18 · 158010.1038/nm.2933 ↗
22. Chatterjee D. K. · Nanomedicine · 2008 · 3 · 7310.2217/17435889.3.1.73 ↗
23. Liu K. · ACS Nano · 2012 · 6 · 405410.1021/nn300436b ↗
24. Shan J. · Adv. Funct. Mater. · 2011 · 21 · 248810.1002/adfm.201002516 ↗
25. Wang C. · Biomaterials · 2011 · 32 · 614510.1016/j.biomaterials.2011.05.007 ↗
26. Qian H. S. · Small · 2009 · 5 · 228510.1002/smll.200900692 ↗
27. Wang C. · Biomaterials · 2011 · 32 · 111010.1016/j.biomaterials.2010.09.069 ↗
28. Tian G. · Small · 2013 · 9 · 192910.1002/smll.201201437 ↗
29. Tian G. · Adv. Mater. · 2012 · 24 · 122610.1002/adma.201104741 ↗
30. Teng X. · J. Am. Chem. Soc. · 2012 · 134 · 834010.1021/ja3016236 ↗
31. Ding Y. · Nanoscale · 2013 · 5 · 1192810.1039/c3nr01840g ↗
32. Boyer J.-C. · Nanoscale · 2010 · 2 · 141710.1039/c0nr00253d ↗
33. Krämer K. W. · Chem. Mater. · 2004 · 16 · 124410.1021/cm031124o ↗
34. Wang Y.-F. · Chem.—Eur. J. · 2012 · 18 · 555810.1002/chem.201103485 ↗
35. Chen G. · ACS Nano · 2012 · 6 · 828010.1021/nn302972r ↗
36. Qiao X.-F. · Nanoscale · 2012 · 4 · 461110.1039/c2nr30938f ↗
37. Shen J. · Small · 2013 · 9 · 321310.1002/smll.201370117 ↗
38. Wang F. · Nat. Mater. · 2011 · 10 · 96810.1038/nmat3149 ↗
39. Wang F. · J. Am. Chem. Soc. · 2008 · 130 · 564210.1021/ja800868a ↗
40. Wang J. · Nat. Mater. · 2014 · 13 · 15710.1038/nmat3804 ↗
41. Wen H. L. · Angew. Chem., Int. Ed. · 2013 · 52 · 1341910.1002/anie.201306811 ↗
42. Dai Y. · Biomaterials · 2012 · 33 · 870410.1016/j.biomaterials.2012.08.029 ↗
43. Chen G. · Chem. Rev. · 2014 · 114 · 516110.1021/cr400425h ↗
44. Bilski P. · Free Radical Biol. Med. · 2002 · 33 · 93810.1016/S0891-5849(02)00982-6 ↗
45. Zhao L. · Theranostics · 2013 · 3 · 24910.7150/thno.5432 ↗